^
Association details:
Biomarker:No biomarker
Cancer:Nasopharyngeal Carcinoma
Drug:Erbitux (cetuximab) (EGFR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Nasopharyngeal cancer: Recurrent/Unresectable or Metastatic (with no surgery or RT option)…Other Recommended Regimens (First-Line)…Carboplatin/Cetuximab
Secondary therapy:
carboplatin